Compare GMED & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMED | PODD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.3B |
| IPO Year | 2012 | 2007 |
| Metric | GMED | PODD |
|---|---|---|
| Price | $75.66 | $159.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | $100.42 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 422.67 | N/A |
| EPS | 0.90 | ★ 1.30 |
| Revenue | ★ $2,938,931,000.00 | $2,708,100,000.00 |
| Revenue This Year | $11.13 | $24.55 |
| Revenue Next Year | $6.28 | $19.18 |
| P/E Ratio | ★ $84.43 | $125.94 |
| Revenue Growth | 16.65 | ★ 30.73 |
| 52 Week Low | $51.79 | $138.79 |
| 52 Week High | $101.40 | $354.88 |
| Indicator | GMED | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 50.12 |
| Support Level | $75.24 | $141.67 |
| Resistance Level | $86.21 | $164.59 |
| Average True Range (ATR) | 3.03 | 6.21 |
| MACD | -0.22 | 0.34 |
| Stochastic Oscillator | 17.18 | 35.50 |
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.